Introduction: Streptococcus pneumoniae can cause
eight geographical areas in the USA, the incidence of IPD ranged from 19.0 to 29.9 per 100,000 general population [5] . However, the surveillance systems, case definitions, and diagnostic standards for IPD in Europe are very heterogeneous making direct comparisons difficult. PCV7 has now been in use for over 10 years and many studies have reported its effectiveness and impact [6] [7] [8] [9] . PCV7 has been replaced by 13-valent 
MATERIALS AND METHODS
The data presented are part of a larger global literature review that assessed the impact of PCV7 in different pneumococcal disease areas. S. pneumoniae causes invasive diseases, such as bacteremic pneumonia, bacteremia, meningitis, and sepsis, and non-IPDs, such as otitis media and upper respiratory tract infections [2] . It was estimated in 2000 that, worldwide, S. pneumoniae was responsible for 826,000 deaths annually in children aged between 1 month and 5 years [3] . and Denmark, respectively [4] . In 1998-1999 in childhood IPD vaccination were analyzed:
four from Australia, 17 from western Europe, and 16 from North America .
The characteristics of these studies are summarized in Table 1 . Eight of the European studies were from Spain, two each from Norway and the UK, and one each from Austria, Belgium, Denmark, Germany, and the Netherlands [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Five of the North American studies used data from the active bacterial core surveillance (ABCs) database; they used the same pre pneumococcal conjugate vaccine (PCV) vaccination period (1998-1999) but analyzed different post-PCV vaccination periods and populations [29] [30] [31] [32] [33] .
Two other studies from North America used the same database from Alaska; they used the same pre-PCV vaccination period (1995) (1996) (1997) (1998) (1999) (2000) The PubMed search was performed using the following terms: (pneumonia OR "invasive pneumococcal disease" OR IPD OR "otitis media" OR death) AND ([pneumococcal AND conjugate AND vaccin*] OR PCV).
In this paper, the data on the impact of PCV7 vaccination in infants on the incidence of IPD (VT and all type) in the general population is summarized, in vaccine-eligible children (direct effect) and in nonvaccineeligible age groups (indirect effect). Studies that were published between January 2000 and March 2011, and performed in western Europe, North America, and Australia were included.
Before/after studies were included if the impact data (percentage change in crude or adjusted incidence rates) were provided or could be calculated. The calculation used was ([incidence prevaccination -incidence postvaccination]/ incidence prevaccination)* 100.
Publications that reported efficacy (i.e., randomized clinical trials), modeling or health economics studies, studies on specific populations (e.g., those with comorbidities, such as HIV positive, patients with sickle cell disease), and studies in specific locations with unknown denominators were excluded.
RESULTS
A total of 1,007 publications were identified from the global search, and after two rounds of screening 84 were selected for inclusion in the global literature review (Fig. 1) . The main reasons for exclusion were: cohort study with no comparative group (epidemiology data); modeling or cost-effectiveness studies; only specific patient subgroups; review articles; and no incidence data or data sufficient for calculating incidence (mainly missing data on denominator). From these, all 37 articles reporting data on the impact of routine [34, 35] . Two of the North American studies were from Canada [41, 42] . Four studies were from Australia [43] [44] [45] [46] .
Impact on VT IPD in Vaccine-Eligible Children
The impact of PCV7 on VT IPD in vaccine-eligible children (<2 or <5 years old, depending on the study) was evaluated in 18 studies (Table 2) .
A reduction in VT IPD incidence was reported in all the studies, ranging from 39.9% in Spain [23] to 99.1% in the USA [32] ; the median rate reduction was 90.1%.
Vaccine Impact on All-Type IPD in Vaccine-

Eligible Children
The impact of PCV7 on all-type IPD in vaccine-eligible children (<2 years or <5 years depending on the study) was evaluated in 30 studies (three from Australia, 15 from Europe, and 12 from North America) ( Table 3 ).
All but one of the studies reported a reduction 
Impact on VT IPD in All Ages
The impact of PCV7 on VT IPD in all ages was evaluated in nine studies that all reported a reduction ranging from 1.4% in the Netherlands [14] to 93.5% in the USA [33] with a median reduction rate of 65.5% (Table 4 ). In the study in the in all-type IPD incidence ranging from 1.7%
(in Spain) [19] [14] .
Impact on VT IPD in Age Groups not Vaccine Eligible (Indirect Effect)
Seven of the eight studies reporting data for nonvaccine-eligible children under 17 years [44] (Appendix Table 1 ). One study reported an increase of 150.0% in children aged 5-17 years in a postvaccination period soon after the introduction of PCV7 [34] ; in a later period, for in the USA [39] . In the remaining age groups, the increased rate reported ranged from 2.4% in the Netherlands [14] to 22.9% in Spain [17] . In one study from Canada, a reduction of 34.0%
and an increase of 9.3% were reported for those aged 65-84 years and 85 year olds and older, respectively [42] .
Impact on All-Type IPD and VT IPD Mortality
The impact of PCV7 vaccination on IPD mortality (both all-type [four studies] and VT [two studies]) was reported from North America only. One study reported reductions for VT IPD mortality across all age groups [33] . In another study, the reduction in VT IPD mortality in children less than 2 years observed was offset with an increase in non-VT IPD mortality resulting in no change [31] . Two studies reported reductions of 62.5% and 57.1% for alltype IPD in vaccine-eligible children [33, 38] .
Two studies reported an overall reduction in all-type IPD mortality in all ages of 37.8% and 75.9% [38, 40] . There was a reduction in all-type IPD mortality for all the nonvaccine-eligible age groups reported ranging from 17.4% in those aged 50 years or older [30] to 50.0% in those aged 25-34 years [38] .
DISCUSSION
The results from this review illustrate that PCV7
has had a significant impact on IPD across all ages through its use in pediatric immunization programs. PCV7 vaccination leads to a reduction in VT IPD in vaccine-eligible children and also to an overall reduction in all-type IPD in these children. PCV7 was also shown to have an indirect impact on VT and all-type IPD in the overall population, although this impact is from 7.1% in those aged 30-49 years in Western Australia [44] to 90.8% in those aged 18-49 years in the USA [33] .
All 13 studies reporting the impact for adults aged 65 years or older (with a total of 16 age groups) showed a reduction in the incidence of VT IPD ranging from 1.1% in the Netherlands [14] to 92.0% in the USA [33] , with a median reduction of 53.8%.
Impact on All-Type IPD in Age Groups not Vaccine Eligible (Indirect Effect)
There was an overall decrease for 12 of the 16 studies that reported data for nonvaccineeligible children aged from over 2 or over 5 years to less than 17 years; the rate reduction ranged from 6.6% for children aged 2 years or older in the UK [25] to 53.4% in children aged 2-4 years in Norway [15] (Appendix Table 2 ).
In the five studies that reported an increase, the rate increase ranged from 9.1% in children aged 5-15 years in Germany [13] In the six age groups in which an increased rate was reported, the increase ranged from 8.5% in nonnative 50-64 year olds in north Queensland, Australia [43] to 119.7% in 20-39 year olds in Alberta, Canada [41] .
Seventeen studies reported data for those aged 65 years and over, with one study from Calgary, Canada reporting data for two age groups; 65-84 years and 85 years and over [42] .
Reductions were reported in 12 of these studies, lower than that seen in vaccine-eligible children.
Despite the increase in non-VT IPD that has been reported, it has been insufficient generally to offset the reduction of VT IPD resulting in an overall reduction of all-type IPD.
The extent of the impact varied across the studies; many factors (and probably a combination of factors) contribute to explain this heterogeneity.
One of these factors is the sero-epidemiology of S. pneumoniae before the introduction of PCV7 and the match with the serotypes in PCV7. In the USA, the serotypes included in PCV7 matched the most prevalent serotypes responsible for IPD, but in other countries and regions, the percentage of IPD due to these seven serotypes varied; thus partly explaining the different impact observed [25, 32] .
The process for PCV7 introduction, its uptake, the recommended schedule, and the implementation of a catch-up program or not also varied between countries. In the USA, where the impact was the greatest, there was a rapid and high uptake after introduction into the NIP for universal vaccination of children less than 2 years old with a 3 + 1 schedule [47] .
However, there was a vaccine shortage in the early stages after introduction into the NIP, so uptake of all four doses was low during this period [48] . In Australia, PCV7 was funded in showed almost 100% reduction [29, 32] .
The studies analyzed in this review used different surveillance systems and case definitions; in addition, it is possible that changes in diagnosis and reporting practices occurred after the introduction of PCV7.
The studies also varied in their geographical coverage, with some able to claim regional or national representation, while some reported data from one or two hospitals, which was the case for four studies from
Spain [17, 20, 23, 24] . In addition, different schedules (3 + 1 and 2 + 1) were used with differing rates of uptake; for example, in 
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